CS21 was a three-arm, randomized (1:1:1), open-label, parallel-group Phase III trial of 12 months' duration incorporating adult male patients with histologically confirmed adenocarcinoma of the ...

Longer time to PSA failure is thought to be desirable as it may be indicative of time to castrationresistant prostate cancer (CRPC) and may delay initiation of second-line therapy, which includes ...